There are currently three FDA-approved PDE4 inhibitors: roflumilast for COPD (Phillips, 2020), apremilast for psoriasis (Queiro Silva et al., 2020), and crisaborole for atopic dermatitis (Hashim et al., 2020). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.